The minimum acceptable performance of blood biomarker tests for diagnosing AD

Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses the minimum acceptable performance of blood biomarker tests for clinical use in diagnosing Alzheimer's disease (AD). She recommends a sensitivity of 90% and a specificity of 85% to avoid getting false positive results from these tests. This can be adjusted slightly in clinics where there is access to confirmatory tests. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.